| Author | Sension, Michael | |
| Author | Andrade Neto, Jose Luiz | |
| Author | Grinsztejn, Beatriz | |
| Author | Molina, Jean Michel | |
| Author | Zavala, Isidro | |
| Author | González-García, Juan | |
| Author | Donnelly, Alice | |
| Author | Phiri, Phillip | |
| Author | Ledesma, Emilio | |
| Author | McGrath, Donnie | |
| Access date | 2018-11-29T14:42:03Z | |
| Available date | 2018-11-29T14:42:03Z | |
| Document date | 2009 | |
| Citation | SENSION, Michael et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. Journal of Acquired Immune Deficiency Syndromes, v. 51, n. 2, p. 153-162, Jun. 2009. | pt_BR |
| ISSN | 1525-4135 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/30322 | |
| Description | The following members of the 067 Study Group participated in subject recruitment, enrollment, medical management, and data collection: William Powderly, MD, St. Louis, MO; Joseph Jemsek, MD, Huntersville, NC; Robert Eng, MD, East Orange, NJ; Dorece Norris, MD and Daniel Seekins, MD, Tampa, FL; Margaret Fischl, MD, Miami, FL; Chris Tsoukas, MD, Montreal, Canada; Livette Johnson, MD, New York, NY; Sharon Walmsley, MD, Toronto, Canada; Juan Sierra, MD, Mexico city, District Federal Mexico; Stefan Esser, MD and Essen, Germany; Prof Reinhold Schmidt, Hannover, Germany; Fernando Aiuti, MD, Rome, Italy; Alain Lafeuillade, MD, Toulon, France; Prof Jacques Reynes, Montpellier, France; Prof Daniel Vittecoq, Villejuif, France; Michele Bentata, MD, Bobigny, France; Prof Frederic Lucht, Saint Etienne, France; Miguel Jimenez Gorgolas, MD, Madrid, Spain; Juan Gonzalez Garcia, MD, Madrid, Spain; Juan Maria Gonzalez Lahoz, MD, Madrid, Spain; Pere Domingo, MD, Barcelona, Spain; Giuliano Stagni, MD, Perugia, Italy; Karam Mounzer, MD, Philadelphia, PA; Margaret Johnson, MD, London, United Kingdom; Gary L. Simon, MD,Washington, DC; Gracy McComsey, MD, Cleveland, OH; Mark Bloch, MD, Darlinghurst, Australia; Cheryl K. MacDonald, MD, Fort Worth, TX; Javier O. Morales Ramirez, MD, San Juan, Puerto Rico; Rohut Talwani, MD, Columbia, SC; Leonard Slater, MD, Oklahoma City, OK; Isidro G. Zavala Trujillo, MD, Zapopan, Jal, Mexico; Prof Jean-Michel Molina, Paris, France; Cecilia Shikuma, MD, Honolulu, HI; Prof Francisco Antunes, Lisbon, Portugal; Beatriz Grinsztejn, MD, Rio de Janeiro, Brazil; Jose Henrique Piloto, MD, Rio de Janeiro, Brazil; Flavio Telles, MD, Curitiba, Brazil; Jose Luiz Andrade, MD, Curitiba, Brazil; Waldo Belloso, MD, Buenos Aires, Argentina; Carlos Zala, MD, Buenos Aires, Argentina; Claudia Rodriguez, MD, Buenos Aires, Argentina; Sergio Lupo, MD, Santa Fe, Argentina; Elida Pallone, MD, Buenos Aires, Argentina; Angel Minguez, MD, Cordoba, Argentina; Arnaldo Casiro, MD, Buenos Aires, Argentina; Norma Luna, MD, Cordoba, Argentina; Jorge Corral, MD, Buenos Aires, Argentina; Abel Jasovich, MD, Buenos Aires, Argentina; Isabel Cassetti, MD, Buenos Aires, Argentina; Luis Noriega, MD, Santiago, Chile; Carlos Perez, MD, Santiago, Chile; MarceloWolff, MD, Santiago, Chile; Juan Echevarria, MD, Lima, Peru; Raul Salazar, MD, Lima, Peru; Andres Paredes, MD, Lima, Peru; and Frederico Rangel, MD, Recife, Brazil. | pt_BR |
| Language | eng | pt_BR |
| Publisher | Lippincott Williams & Wilkins | pt_BR |
| Rights | restricted access | pt_BR |
| Title | Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir | pt_BR |
| Type | Article | |
| DOI | 10.1097/QAI.0b013e3181a5701c | |
| Abstract | Objective: The primary objective was to compare the change in fasting low-density lipoprotein (LDL) cholesterol from baseline to week 12 between patients receiving an atazanavir-containing regimen and those receiving comparator protease inhibitor (PI) regimens. Design: AI424-067 was a 48-week, open-label, randomized, prospective study of 246 patients on PI-based regimens with hyperlipidemia [fasting LDL cholesterol >130 mg/dL (>3.4 mmol/L)] and with HIV RNA <50 copies per milliliter. Patients were randomized to switch to atazanavir (400 mg once daily) on day 1 (immediate switch) or maintain current PI regimen for the first 24 weeks, then switch to atazanavir (delayed switch). Methods: Plasma lipid levels were compared with baseline values at weeks 12, 24, and 48. Safety, viral load, and CD4 profiles were also evaluated. Results: At week 12, the mean percent changes in LDL cholesterol from baseline for the immediate-switch and delayed-switch groups were -15% and +1%, respectively (P < 0.0001). Favorable LDL cholesterol levels in the immediate-switch group were sustained through week 48. Both groups maintained comparable virologic control. Switching to atazanavir did not produce a significant change in safety or tolerability. Conclusions: A switch-either immediate or delayed-from a boosted or unboosted PI to unboosted atazanavir in patients with hyperlipidemia was associated with improvements in plasma lipid parameters without loss of virological suppression. | pt_BR |
| Affilliation | North Broward Hospital District. HIV Clinical Research. Lauderdale, FL, USA. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Paraná. Curitiba, PR, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Hôpital Saint-Louis. Paris, France. | pt_BR |
| Affilliation | Hospital Dr. Angel Leano. Consultorio de Infectiologica. Jalisco, México. | pt_BR |
| Affilliation | Hospital La Paz. Madrid, España. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Pharmaceutical Research Institute. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Pharmaceutical Research Institute. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Pharmaceutical Research Institute. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Pharmaceutical Research Institute. Wallingford, CT, USA. | pt_BR |
| Subject | Antiretroviral therapy | pt_BR |
| Subject | Atazanavir | pt_BR |
| Subject | Cholesterol | pt_BR |
| Subject | Lipids | pt_BR |
| Subject | Protease inhibitor | pt_BR |
| Embargo date | 2030-12-31 |
Files in this item
This item appears in the following Collection(s)
-
INI - Artigos de Periódicos [3645]